<DOC>
	<DOCNO>NCT02332824</DOCNO>
	<brief_summary>The primary objective study test efficacy safety daily oral dos TAK-272 5 mg , 20 mg , 40 mg 80 mg patient type 2 diabetes mellitus microalbuminuria randomize , double-blind , placebo-controlled , parallel-group comparison order determine clinical dose TAK-272 .</brief_summary>
	<brief_title>A Phase 2 Dose-finding Study TAK-272 Patients With Type 2 Diabetes Mellitus Microalbuminuria</brief_title>
	<detailed_description>This phase 2 dose-finding study test efficacy safety daily oral dos TAK-272 5 mg , 20 mg , 40 mg 80 mg patient type 2 diabetes mellitus microalbuminuria randomize , double-blind , placebo-controlled , parallel-group comparison order determine clinical dose TAK-272 . In addition , define candesartan cilexetil 8 mg group reference group double-blinded fashion , clinical benefit TAK-272 exploratorily determine .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>In opinion investigator , subject capable understanding comply protocol requirement The subject sign date write , informed consent form require privacy authorization prior initiation study procedures The subject either male female age ≥ 20 &lt; 75 year time consent The subject earlystage nephropathy ( Stage 2 ) patient type 2 diabetes mellitus The subject patient type 2 diabetes mellitus certain diet therapy and/or exercise therapy ( ) The subject 's blood glucose , blood pressure lipid stably control , drug change dose change therapeutic drug hypertension , therapeutic drug diabetes mellitus , therapeutic drug dyslipidemia hyperlipidemia require throughout study period judge investigator A male subject nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose A female subject childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent 1 month completion study The subject receive TAK272 previous clinical study The subject immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may give consent participate duress The subject history hypersensitivity allergy TAK272 , candesartan cilexetil RAS inhibitor ( ACE inhibitor , ARBs DRIs ) The subject need take prohibit medication study period The subject hyperkalemia ( e.g . serum potassium ≥ 5.0 mEq/L Week 8 4 pretreatment period , require regular use potassium adsorbent ) onset hyperkalemia within 2 year prior start pretreatment period The subject renal disease type 2 diabetic nephropathy ( e.g . patient renal sclerosis , acute chronic glomerular nephritis , polycystic nephropathy ) . The subject bilateral unilateral renal artery stenosis The subject require regular use nonsteroidal antiinflammatory drug ( exclude lowdose aspirin locallyacting agent topical drug ) ( e.g . rheumatoid arthritis patient , osteoarthritis patient , low back pain patient ) The subject history cardiovascular disease list within 2 year prior start pretreatment period : Heart disease : myocardial infarction , coronary arterial revascularization Cerebrovascular disease : cerebral infarction ( exclude lacunar infarction ) , cerebral hemorrhage , transient ischemic attack The subject cardiovascular disease list : Heart disease : angina pectoris , arrhythmia , congest heart failure require medication Vascular disease : arteriosclerosis obliterans symptoms e.g . intermittent claudication The subject clinically significant hepatic disorder ( e.g . either ALT AST ≥ 2.5 time upper limit normal start pretreatment period ( Week 8 ) Week 4 pretreatment period ) The subject complication malignant tumor If female , subject pregnant lactating , plan become pregnant donate ovum sign informed consent form , study period , within 1 month end study If male , subject intend donate sperm course study 12 week thereafter The subject judge investigator ineligible reason The subject join another clinical trial postmarketing study within 30 day prior start pretreatment period The subject administer study drug within 12 week prior start pretreatment period The subject history drug abuse ( define use illegal drug ) alcohol dependency within 2 year prior start pretreatment period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>